《新股表現》創勝(06628.HK)暗盤平開報16元
根據輝立交易平臺顯示,明天掛牌的創勝集團-B(06628.HK)暗盤平開報16元欠承接,掉頭低見13.68元,現報14元,較上市價16元,低12.5%,成交6.6萬股。
創勝是一家集發現、研發、製造及業務拓展能力爲一體臨牀階段生物製藥公司,管理團隊主要業務(包括臨牀開發、監管準入及業務拓展)位於中國及美國。集團利用高效監管審批路徑以加快進行在美國研究用新藥(IND)申請與前期臨牀試驗,以及推進在中國來自龐大患者人羣的巨大醫療需求缺口的適應症的臨牀試驗。
創勝是次上市共發售4,033萬股,並已引入亞洲生命科學投資公司LAV Amber、新加坡淡馬錫、卡塔爾投資局旗下QIA及國企結構調整基金4名基石投資者,合共認購2,808.3萬股;其中10%公開發售獲近60倍超購,已啓動回撥機制佔比增至40%,認購一手中籤率15%;股份以招股範圍(15.8-16元)上限定價,料集資淨額約5.744億元,主要用作管線候選產品研發、爲進行中及計劃中臨牀與臨牀前試驗、籌備註冊備案和其他與商業化四款主打產品有關步驟或活動撥資;以及用作擴充管線和開發技術業務發展等。上市聯席保薦人分別爲高盛及中金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.